Xenetic Biosciences XBIO 2024 Corporate Presentation

Xenetic Biosciences presents its DNase I oncology platform technology aimed at improving cancer immunotherapies by targeting neutrophil extracellular traps (NETs). The proprietary enzyme digests DNA to expose cancer cells and overcome resistance to chemotherapy and checkpoint inhibitors across multiple high-value cancer indications including pancreatic cancer.